<div id="readability-page-1"><p>FibroBiologics, Inc. (<span>FBLG</span>) has disclosed a new risk, in the Corporate Activity and Growth category.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>FibroBiologics, Inc. faces substantial doubt about its ability to continue as a going concern, given recurring operating losses, negative operating cash flows, and reliance on uncertain future financings and collaborations. This doubt could pressure its share price, constrain access to capital, and limit counterparties’ willingness to enter or maintain business relationships, heightening the risk of further program cuts or loss of investor capital.</p> <p>The average FBLG <span>stock price target</span> is $19.00, implying 1,201.37% upside potential.</p> <p>To learn more about FibroBiologics, Inc.’s risk factors, <span>click here</span>.</p></div>

FBLG

SBIO

LABU

<p>FibroBiologics, Inc. (FBLG) has raised concerns about its ability to continue as a going concern due to ongoing operating losses and negative cash flows. The company relies on uncertain future financing, which may impact its share price and limit capital access. This situation could lead to program cuts and loss of investor capital. Despite these challenges, the average stock price target for FBLG is $19.00, suggesting a potential upside of 1,201.37%.</p>

Tip Ranks

Fibrobiologics

ALPS Medical Breakthrough

VanEck Biotech ETF

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

FibroBiologics Warns of ‘Going Concern’ Risk as Losses Mount and Funding Outlook Darkens